AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo CBD
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo THC
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo THC
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
Study NCT05631379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ESPEN-EASO criteria for sarcopenic obesity
Description: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
Study NCT05631379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic Nutritional Index (PNI)
Description: Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
Study NCT05631379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The high-sensitivity modified Glasgow prognostic score
Description: The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
Study NCT06777459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Description: Nitrate-rich beetroot juice, \~750 mg NO3- /d
Study NCT06776887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks
Description: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .
Study NCT06776887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks
Description: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: Axicabtagene Ciloleucel
Description: No investigational product will be administered
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: Brexucabtagene Autoleucel
Description: No investigational product will be administered
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: Anitocabtagene autleucel
Description: No investigational product will be administered
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: KITE-753
Description: No investigational product will be administered
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: KITE-197
Description: No investigational product will be administered
Study NCT05041309 — intervention group
Intervention type: BIOLOGICAL
Intervention: KITE-363
Description: No investigational product will be administered
Study NCT05476601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus
Description: The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
Study NCT05036070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model C0001
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study NCT05036070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model ZCB00
Description: Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study NCT06241677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase or tenecteplase
Description: Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
Study NCT05626920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram 250 mg
Description: Disulfiram treatment
Study NCT05626920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT06545045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Strategy Training (MCST)
Description: The MCST group will follow procedures for the Cognitive Orientation to daily Occupational Performance intervention. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, the therapist introduces the approach to the subject and teach a global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition. The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
Study NCT06545045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Control Group
Description: Weekly contact will be made via telephone call to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce cognitive symptoms. The content of each of these meetings will be tracked in intervention notes.
Study NCT06646315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Description: The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation 60-Fr non stricture
Description: Dilation of patients with subjective dysphagia and normal endoscopy
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham dilator for patients with subjective dysphagia and normal endoscopy
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non severe stricture - dilation with 60-Fr
Description: Dilation of non severe stricture with 60-Fr dilator
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non severe stricture - dilation with 46-Fr
Description: Dilation of non severe stricture with 46-Fr dilator
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Severe stricture - dilation with 51-Fr
Description: Dilation of a severe stricture with 51-Fr dilator
Study NCT04542551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Severe stricture - dilation with 42-Fr
Description: Dilation of a severe stricture with 42-Fr dilator
Study NCT04296409 — intervention group
Intervention type: OTHER
Intervention: Turkish Deglutition Handicap Index
Description: Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
Study NCT06367426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDN-A-0101 (SAD)
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture
Study NCT06367426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDN-A-0101 (MAD)
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture
Study NCT06367426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SAD)
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture
Study NCT06367426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MAD)
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture
Study NCT06585007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Progression-directed therapy (stereotactic body radiation therapy)
Study NCT06585007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metastasectomy
Description: Progression-directed therapy (metastasectomy)
Study NCT05924971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study NCT06043427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m²
Study NCT06043427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m²
Study NCT06043427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg
Study NCT06043427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg
Study NCT06043427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Dose and schedule to be assigned at enrollment
Study NCT06402344 — intervention group
Intervention type: OTHER
Intervention: Hormonal implant
Description: History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
Study NCT06402344 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Young women who never used any hormonal implant.
Study NCT06058832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Shockwave Therapy
Description: patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
Study NCT06058832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel Exercises
Description: * The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening
Study NCT06190301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intralesional Rituximab Injection
Study NCT06190301 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Site Radiation Therapy
Description: Involved Site Radiation Therapy
Study NCT06544655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986484
Description: Specified dose on specified days
Study NCT06544655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT06350097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .
Study NCT06350097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .
Study NCT06350097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Study NCT06082518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monoplace Hyperbaric Chamber (Class III medical device).
Description: 40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada.
Study NCT06373822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating-mirna
Description: A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
Study NCT06458322 — intervention group
Intervention type: OTHER
Intervention: Home dialysis or In-Center dialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
Study NCT06103838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine injection
Description: 370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
Study NCT06103838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
Study NCT05957718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TKTX cream
Description: TKTX cream was used in several studies on Tatto and laser
Study NCT05957718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKTX cream
Description: TKTX cream was used in several studies on Tatto and laser
Study NCT04340232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Subjects will receive a 2 mg oral dose of baricitinib.
Study NCT05554510 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: No interventions planned. Observational data collection only.
Study NCT06038578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
Study NCT06038578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Study NCT06038578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Study NCT05319925 — intervention group
Intervention type: OTHER
Intervention: Patient reported outcome measure
Description: Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
Study NCT06544499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod
Study NCT06544499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Intravenous infusion of placebo
Study NCT06038578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study NCT06038578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study NCT05338086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB09 (denosumab biosimilar)
Description: PFS 60 mg/mL solution,
Study NCT05338086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB09 (denosumab biosimilar)
Description: PFS 60 mg/mL solution,
Study NCT05338086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia
Description: PFS 60 mg/mL solution, administered as subcutaneous injection
Study NCT05338086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: at least 1000 mg daily
Study NCT05338086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental Calcium
Description: at least 1000 mg daily
Study NCT05338086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: at least 400 IU daily
Study NCT05338086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: at least 400 IU daily
Study NCT04950283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance examination, anthropometric and metabolic characterization
Description: Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
Study NCT05588206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherap
Description: A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
Study NCT06503237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CART cells will be given IV at split doses.
Description: Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
Study NCT05007691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
Study NCT05784571 — intervention group
Intervention type: OTHER
Intervention: Body Composition Assessment
Description: Assessment of body composition using bioelectrical impedance analysis.
Study NCT05784571 — intervention group
Intervention type: OTHER
Intervention: Modified Physical Performance Test
Description: A test of physical functioning
Study NCT05784571 — intervention group
Intervention type: OTHER
Intervention: Hand grip strength
Description: A test of hand grip strength using a hand dynamometer.
Study NCT05784571 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: Self-paced test of walking capacity.
Study NCT05784571 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of blood glucose and insulin
Description: Blood will be drawn for measurement of glucose and insulin.
Study NCT06462157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training
Description: Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
Study NCT05088512 — intervention group
Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study NCT06347211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm
Description: Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension.